Precision Oncology Framework Using Circulating Tumor Cells
International Journal of Molecular Sciences · 10.06.2025 · 26 (12) · 5539
DOI: 10.3390/ijms26125539 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.06.2025. Verfasst von Fumihiko Kakizaki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Personalized Cancer Medicine, Graduate School of Medicine, Kyoto University, 53 Shogoin-Kawahara-cho, Sakyo-Ku, Kyoto 606-8507, Japan. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Precision Medicine, Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, AFI Corporation, Kyo Diagnostics K.K..
Abstract (Originalsprache)
Circulating tumor cells (CTCs) are multifaceted biomarkers with significant potential for precision oncology, offering opportunities to refine diagnoses and personalize treatments across various cancer types, including colorectal and breast cancer. CTC assays serve as reliable prognostic indicators, even during chemotherapy and/or molecularly targeted therapies. Notably, CTCs exhibit heterogeneity that gradually develops during carcinogenesis and becomes more pronounced in advanced disease stages. These intra- and intertumoral heterogeneities pose challenges, particularly when drug-resistant clones emerge following therapy. The dynamic behavior of CTCs provides valuable insights into treatment response and prognosis. Extensive efforts have led to the development of technologies for effective CTC isolation, accelerating their clinical implementation. While both CTC and circulating tumor DNA (ctDNA) tests offer prognostic value, they reflect different aspects of tumor biology: CTC counts indicate tumor progression, while ctDNA levels correlate with tumor burden. The combined analysis is expected to yield complementary insights. CTC tests are feasible in general hospitals and may serve as tumor markers comparable to, or even superior to, conventional markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) for colorectal cancer, and CA15-3 for breast cancer. Early incorporation of CTC tests into routine blood panels appears to be a rational and promising approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Personalized Cancer Medicine, Graduate School of Medicine, Kyoto University, 53 Shogoin-Kawahara-cho, Sakyo-Ku, Kyoto 606-8507, Japan.
- AFI Corporation, Medical Innovation Center, Building, Kyoto University, 53 Shogoin-Kawahara-cho, Sakyo-Ku, Kyoto 606-8507, Japan.
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-Ku, Kyoto 606-8507, Japan.
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-Ku, Kyoto 606-8507, Japan.
ORCID-Profile: Fumihiko Kakizaki, Hiroyuki Miyoshi, Kazutaka Obama
Förderung
- Japan Agency for Medical Research and Development
- AFI Corporation
- Kyo Diagnostics K.K.
- SCREEN Holdings Co., Ltd.
Zitieren
APA
Kakizaki, F., Oshiro, K., Enoki, Y., Kawanishi, K., Masuda, N., Maekawa, H., Matsubayashi, J., Kawashima, M., Miyoshi, H., Takemura, Y., & Obama, K. (2025). Precision Oncology Framework Using Circulating Tumor Cells. International Journal of Molecular Sciences, 26(12), 5539. https://doi.org/10.3390/ijms26125539
Vancouver
Kakizaki F, Oshiro K, Enoki Y, Kawanishi K, Masuda N, Maekawa H, et al. Precision Oncology Framework Using Circulating Tumor Cells. International Journal of Molecular Sciences. 2025;26(12):5539. doi:10.3390/ijms26125539
BibTeX
@article{Kakizaki2025,
author = {Kakizaki, Fumihiko and Oshiro, Kyoichi and Enoki, Yuya and Kawanishi, Kana and Masuda, Norikazu and Maekawa, Hisatsugu and Matsubayashi, Jun and Kawashima, Masahiro and Miyoshi, Hiroyuki and Takemura, Yukitoshi and Obama, Kazutaka},
title = {Precision Oncology Framework Using Circulating Tumor Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {12},
pages = {5539},
doi = {10.3390/ijms26125539}
}
EUVIMED